1. Alksne, H., Lieberman, L., and Brill, L., 1967, A conceptual model of the life cycle of addiction, Int. J. Addict. 2: 221.
2. Angst, J., Autenrieth, V., Brem, F., Koukkou, M., Meyer, H., Stassen, H. H., and Storck, U., 1979, Preliminary results of treatment with (3-endorphin in depression in: Endorphins in Mental Health Research (E. Usdin, W. E. Bunney, Jr., and N. S. Kline, eds.), pp. 518–528, Oxford University Press, London.
3. Berger, P., Watson, S. J., Akil, H., and Barchas, J. D., 1979, Naloxone administration in chronic hallucinating schizophrenic patients, in: Endorphins in Mental Health Research ( E. Usdin, W. E. Bunney, Jr., and N. S. Kline, eds.), pp. 423–434, Oxford University Press, London.
4. Bradford, H. A., Hurley, F., Golondzowski, D., and Dorrier, C., 1976, Interim report on clinic intake and safety data collected from 17 NIDA-funded naltrexone studies, in: Narcotic Antagonists: Naltrexone Progress Report (D. Julius and P. Renault, eds.), National Institute on Drug Abuse Research Monograph Series 9, p. 163, DHEW, Washington, D.C.
5. Brill, L., Nash, G., and Langood, J., 1972, The dynamics of de-addiction—A pilot study, in: Major Modalities in the Treatment of Drug Abuse ( L. Brill and L. Lieberman, eds.), pp. 287–307, Behavioral Publications, New York.